Tamim Niazi, MDCM, discusses key findings from the phase 3 DASL-HiCaP study presented at the 2026 ESMO Congress.

Olomorasib is an investigational, selective KRAS G12C inhibitor with central nervous system activity. The phase 3 SUNRAY-01 ...

John Bridgewater, BA, MBBS, MRCP, PHD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.

Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, ...

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...

1. Oliai C, Feldman DR, Slotkin E, et al. Clinical safety and efficacy of ixotatug vedotin (TORL-1-23), a claudin 6-targeted ADC, as monotherapy in germ cell tumors (GCT). Presented at: 2026 ESMO ...

Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. The oral EGFR inhibitor sunvozertinib (Zegfrovy) is ...

These developments also strengthen the rationale for next-generation sequencing (NGS) in patients with early-stage disease.

Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and ...